Journal Club  by unknown
Kidney International (2010) 77             481
journal  c lubhttp://www.kidney-international.org
© 2010 International Society of Nephrology
Kidney International (2010) 77, 481–482. doi:10.1038/ki.2010.2
Bicarbonate-sensing soluble 
adenylyl cyclase is a potential sensor 
for acid/base homeostasis
Tresguerres et al., Proc Natl Acad Sci USA 2010; 107: 442–447; doi:10.1073/
pnas.0911790107
Acid/base balance is tightly regulated; to maintain acid/base 
homeostasis, animals have developed specialized epithelia that 
regulate the concentrations of HCO3− and CO2, and thus pH. 
Indeed, the ion-transporting mechanisms in cells of acid/base 
regulatory organs show remarkable similarities throughout ani-
mal phyla. Yet the fundamental question of how acid/base changes 
are sensed remains unsolved. From analogy with other biologi-
cal sensors, it is likely that an acid/base sensor detects deviations 
from a set point and induces compensatory responses. Soluble ade-
nylyl cyclase (sAC), a cytosolic enzyme distinct from the widely 
studied transmembrane adenylyl cyclases (tmACs), was isolated 
recently in the male germ line, where HCO3− is a critical regula-
tor of cell activity. Unlike tmACs, which are hormone-responsive 
and G protein−regulated enzymes, sAC is directly stimulated 
by bicarbonate. Interestingly, mammalian sAC was found to be 
most similar to AC from cyanobacteria, and bicarbonate regu-
lation of cyclase activity is conserved in these early-life-form 
enzymes. Moreover, sAC was also found to be abundant in other 
bicarbonate-responsive organs, such as the kidney and the choroid 
plexus, suggesting that bicarbonate-induced cAMP signaling could 
be an important regulator of acid/base homeostasis. Hence, as a 
signaling enzyme directly modulated by bicarbonate, sAC could 
be a potential acid/base sensor. To test this hypothesis, Tresguerres 
et al. examined its role in the dogfish shark. Elasmobranchs (sharks, 
rays, and relatives) are fish that evolved about 400 million years 
ago. They regulate acid/base balance in their gills, where numerous 
acid- and base-secreting cells are functionally analogous to those in 
the mammalian kidney. In the gill base-secreting cells, the vacuolar 
proton pump (V-H+-ATPase) translocates from the cell cytoplasm 
into the basolateral membrane in response to blood alkalosis, a 
natural post-feeding elevation in blood bicarbonate and pH. Of 
course, basolateral V-H+-ATPase secretes protons into the blood 
and induces apical bicarbonate secretion. The authors found that, 
like mammalian sAC, the dogfish enzyme was activated by HCO3− 
and, in addition, could be inhibited by two structurally distinct 
small molecules. They also found that dogfish sAC was expressed 
in the gill epithelium (Figure) and that one of its downstream 
effects was to insert vacuolar proton pumps into the basolateral 
membrane. Importantly, enzyme inhibition during alkalosis dem-
onstrated that its activity was critical for maintaining systemic pH 
and HCO3− concentration in the whole organism.
Because sAC orthologs are present throughout metazoans, and 
mammalian sAC is expressed in acid/base regulatory organs, these 
results suggest that the enzyme is a critical component of the acid/
base sensing mechanism.
Juan Oliver
Mutations in the formin gene 
INF2 cause focal segmental 
glomerulosclerosis
Brown et al., Nat Genet 2010; 42: 72–76; doi:10.1038/ng.505
Focal segmental glomerulosclerosis (FSGS) is a renal histologi-
cal picture found in a large variety of conditions with different 
causes. Alterations of the podocytes, such as foot process efface-
ment, are very prominent in FSGS. Over the past few years, several 
genes have been identified that, when mutated, cause inherited 
FSGS (for example, α-actinin-4, TRPC6, and NPHS2) and/or 
the related nephrotic syndrome. Identification of these genes has 
greatly accelerated our understanding of glomerular podocyte 
function and disease. With this in mind, Brown et al. genotyped 
members of a large family with apparent autosomal dominant 
FSGS using a dense set of single-nucleotide polymorphism mark-
ers, followed by focused microsatellite genotyping. They identified 
a locus for FSGS in this family that overlapped with a larger locus 
that the authors had identified previously in another large family 
with a similar clinical course. Hence, the authors suspected that 
FSGS in both families was caused by a defect in the same gene. 
By sequencing multiple genes in this region, the authors detected 
nine independent non-conservative missense mutations in INF2, 
which encodes a member of the formin family of actin-regulating 
proteins. Importantly, these mutations were found to segregate 
with FSGS in 11 unrelated families and to alter highly conserved 
amino acid residues. Location of INF2 in the kidney by in situ 
hybridization and by antibody staining (Figure) showed it to be 
expressed in podocytes. In vitro studies with podocytes showed 
that the mutant forms of INF2 behave differently from the wild-
type protein. Podocytes are actin-rich, interdigitating cells that 
likely need to react to a unique set of physical stresses.
Dysregulation of the podocyte cytoskeleton is a common feature of 
glomerular diseases, and this work’s important finding that alterations 
sAC is present in the gill of dogfish. Top: Immunofluorescence using anti-
dogfish sAC (green) in gill. Nuclei were labeled with DAPI (blue). Bottom: 
Staining using anti-dogfish sAC antisera preabsorbed with excess 
immunizing peptide.
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in podocyte-expressed formin cause FSGS again highlights the critical 
role of actin polymerization in podocyte homeostasis.
Juan Oliver
EPO-induced upregulation  
of endothelial NOS but not  
vascular endothelial growth factor 
prevents ischemic damage  
in musculocutaneous tissue
Rezaeian et al., Lab Invest 2010; 90: 40–51; doi:10.1038/labinvest.2009.117
Recent findings revealed tissue protection by erythropoietin 
(EPO) independent of its hematopoietic properties in a variety of 
organ systems suffering from ischemia. Rezaeian et al. investigated 
the role of microcirculatory, angiogenic, and cellular mechanisms 
of systemic EPO administration in a model of persistent ischemic 
injury in musculocutaneous tissue in mice. They assigned mice 
to five experimental groups equipped with a randomly perfused 
flap fixed in a dorsal skinfold chamber, while the sixth group did 
not undergo flap preparation: EPO, l-NAME, EPO and l-NAME, 
EPO and bevacizumab, untreated flap, and nonischemic chamber 
(control). They carried out intravital fluorescence microscopic 
analysis of microhemodynamics, apoptotic cell death, macromo-
lecular leakage, and angiogenesis over a 10-day period and used 
immunohistochemical analysis to study the protein expression of 
endothelial nitric oxide synthase (eNOS) and vascular endothelial 
growth factor (VEGF). Increased expression of eNOS in EPO-
administered mice correlated with significant arteriolar dilation 
and thus increased blood flow, resulting in a maintained func-
tional capillary density (FCD) at day 10. In addition, EPO induced 
a VEGF upregulation, which was associated with newly formed 
capillaries. Also, EPO was able to reduce ischemia-induced apop-
totic cell death and to significantly reduce flap necrosis. In con-
trast, coadministration of l-NAME abolished EPO-mediated 
tissue protection by abrogating the dilatory effect, resulting in 
reduced FCD and tissue survival without counteracting angiogen-
esis and apoptotic cell death. In contrast, the additional adminis-
tration of bevacizumab did not influence the beneficial effect of 
EPO on flap survival despite abrogating angiogenesis.
This study shows that EPO administration protects musculo-
cutaneous tissue from ischemic necrosis as a consequence of an 
eNOS-dependent arteriolar hyperperfusion maintaining capillary 
perfusion, thus representing a promising approach to pharma-
cologically protect ischemically challenged tissue. Although in 
experimental conditions EPO seems to be partly protective in renal 
ischemia/reperfusion, the few clinical trials were less convincing. 
This paper on the use of EPO in musculocutaneous tissue with 
ischemic damage unravels the main protective mechanism, opening 
new perspectives in the application of EPO in ischemic pathology.
Marc De Broe
Glycemic control  
and cardiovascular events  
in diabetic hemodialysis patients
Drechsler et al., Circulation 2009; 120: 2421–2428; doi:10.1161/
CIRCULATIONAHA.109.857268
The treatment of diabetes mellitus in patients with end-stage renal 
disease (ESRD) is difficult because of the limitations in the litera-
ture linking markers of glycemic control with outcomes. Studies 
suggest that hemoglobin A1c (HbA1c) may not reflect average 
blood glucose levels as well in patients with ESRD. Further, obser-
vational studies have not demonstrated the same strong link 
between HbA1c and mortality as is seen in patients with normal 
kidney function. Drechsler et al. analyzed the association between 
cause-specific mortality and HbA1c among the patients with 
type 2 diabetes mellitus (T2DM) enrolled in the German Diabetes 
and Dialysis (4D) trial.1 The 4D trial randomized more than 1200 
ESRD patients with T2DM to atorvastatin or placebo and com-
pared the rates of several cardiovascular outcomes. As in other 
studies, the risk of all-cause mortality was not strongly associated 
with an increased risk of death (hazard ratio (HR) per 1% increase 
in HbA1c, 1.09; 95% confidence interval (CI), 1.02–1.17). Analyses 
stratified on cause of death suggest that this modest association is 
a result of a stronger association between sudden death as a cause 
(HR per 1% increase in HbA1c, 1.21; 95% CI, 1.06–1.38) and all 
other causes except sudden death (HR per 1% increase in HbA1c, 
1.04; 95% CI, 0.96–1.13). In multiple models, factors like potas-
sium, dysrhythmias, and electrocardiographic changes, such as 
those indicating left ventricular hypertrophy, were added one at 
a time to gain insight into potential mechanism. The association 
between HbA1c and sudden death was not significantly changed 
by any of these variables.
The association between HbA1c and sudden death is biologically 
plausible in that hyperglycemia plays a role in the development of 
microangiopathy and impaired myocardial vasodilator function 
as well as the generation of highly reactive free radicals that result 
in oxidative stress. Although the limitations of HbA1c as a marker 
of glycemic control and our limited insight into goal levels of gly-
cemic control for ESRD patients are unchanged, this analysis gives 
important clues as to how to approach the puzzle of sudden death 
in dialysis patients.
Lydia Szczech
1N Engl J Med 2005; 353: 238–248.
Immunofluorescence staining of mouse kidney with the nuclear stain DAPI 
(blue) and antibodies against nephrin (red) and INF2 (green). INF2 staining 
is observed in the glomeruli in an epithelial-cell pattern. Arrows show areas 
of nephrin and INF2 localization. Arrowheads show a cell expressing INF2 
but not nephrin.
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